Zota Health Care FY26 Revenue Up 84% YoY to ₹538.66 Crore; Davaindia Business Grows to ₹417.41 Crore
Zota Health Care's FY26 revenue rose 84% YoY to ₹538.66 Crore, driven by Davaindia's growth to ₹417.41 Crore. Davaindia expanded to 2,579 stores (1,656 COCO, 923 FOFO). The company acquired 100% stake in Curexis and has appointed Suniel Shetty and M.S. Dhoni as brand ambassadors. The company aims to reach 5,000+ Davaindia stores by FY29.
The strong financial results, rapid expansion of Davaindia, and acquisition of Curexis are likely to have a significant positive impact on the company's performance and market position.
The announcement highlights strong revenue growth, significant expansion of the Davaindia network, and strategic acquisitions, indicating positive developments for the company.
Zota Health Care Limited announced its investor presentation on May 23, 2026. The presentation highlights the company's performance and strategic initiatives. Key financial highlights for FY26 (Consolidated) include Revenue from Operations of ₹538.66 lakhs (₹538.66 Crore), Gross Profit of ₹324.69 lakhs (₹324.69 Crore), and Gross Merchandise Value of ₹457.06 lakhs (₹457.06 Crore). As of March 31, 2026, Davaindia has 2,597 operational stores, comprising 1,656 COCO stores and 923 FOFO stores. The company has a portfolio of over 2,000 SKUs in Davaindia and more than 4,000 products covering major therapeutic segments. Zota Health Care has an 87.78% stake in Everyday Herbal Group, enhancing its supply chain and OTC product offerings. The company serves 30+ export markets and has received 325 product approvals out of 586 dossier applications. In FY26, Davaindia's revenue contribution was 77%, domestic marketing 13%, exports 6%, and Everyday Herbal Group 3%.
Zota Health Care's journey includes incorporation in 2000, acquisition of Sayona Medicare's brand names in 2004, and Mexon Health Care Limited's trademark in 2007. Davaindia was introduced in 2017, and by 2026, it expanded to 2,579 active stores. The company successfully completed a QIP of ₹350 crore and acquired 100% stake in Curexis. Brand ambassadors Suniel Shetty and M.S. Dhoni have been appointed.
Ketankumar Zota (Chairman) noted that FY26 was a defining year with strong execution and accelerated expansion of the Davaindia network, and the addition of 997 new stores. The company intends to moderate the pace of expansion over the next two quarters, focusing on improving profitability and optimizing store performance. The long-term vision is to reach 5,000+ Davaindia stores by FY29.
What to do with a filing like this
Zota Health Care LImited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zota Health Care LImited. Read the original for the full detail.